EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN'S DISEASEIN CHILDREN

• Main Authors: E. G. Tsimbalova (Author), A. S. Potapov (Author), M. M. Venedictova (Author), F. F. Shavrov (Author)
• Format: Book
• Published: "Paediatrician" Publishers LLC, 2012-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This paper shows the research results of the biological therapy with chimeric monoclonal antibody to tumor necrosis factor (TNF) (infliximab). 33 children aged 6 to 18 years with various forms of Crohn's disease were enrolled in the study. Therapy duration ranged from 3 months to 1 year or more...